Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease.

A novel biodegradable brain drug delivery system, the lactoferrin (Lf) conjugated polyethylene glycol-polylactide-polyglycolide (PEG-PLGA) nanoparticle (Lf-NP) was constructed in this paper with its in vitro and in vivo delivery properties evaluated by a fluorescent probe coumarin-6. Lf was thiolated and conjugated to the distal maleimide function surrounding on the pegylated nanoparticle to form Lf-NP. TEM observation and ELISA analysis confirmed the existence of active Lf on the surface of Lf-NP. The results of qualitative and quantitative uptake studies of coumarin-6 incorporated Lf-NP showed a more pronounced accumulation of Lf-NP in bEnd.3 cells than that of unconjugated nanoparticle (NP). Further uptake inhibition study indicated that the increased uptake of Lf-NP was via an additional clathrin mediated endocytosis processes. Following intravenous administration, a near 3 fold of coumarin-6 was found in the mice brain carried by Lf-NP compared to that carried by NP. Intravenous injection of urocortin loaded Lf-NP effectively attenuated the striatum lesion caused by 6-hydroxydopamine in rats as indicated by the behavioral test, the immunohistochemistry test and striatal transmitter content detection results. The cell viability test and CD68 immunohistochemistry demonstrated the acceptable toxicity of the system. All these results demonstrated that Lf-NP was a promising brain drug delivery system with reasonable toxicity.

[1]  Wei Lu,et al.  Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[2]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[3]  E. Morgan,et al.  Restricted transport of anti‐transferrin receptor antibody (OX26) through the blood–brain barrier in the rat , 2001, Journal of neurochemistry.

[4]  V. Labhasetwar,et al.  Characterization of nanoparticle uptake by endothelial cells. , 2002, International journal of pharmaceutics.

[5]  Jayanth Panyam,et al.  Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles. , 2003, International journal of pharmaceutics.

[6]  Xinguo Jiang,et al.  Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[7]  D. Legrand,et al.  Characterization of two kinds of lactotransferrin (lactoferrin) receptors on different target cells. , 1994, Advances in experimental medicine and biology.

[8]  Linyin Feng,et al.  Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model , 2010, Journal of the Neurological Sciences.

[9]  M. Mattson,et al.  Urocortin, But Not Urocortin II, Protects Cultured Hippocampal Neurons from Oxidative and Excitotoxic Cell Death via Corticotropin-Releasing Hormone Receptor Type I , 2002, The Journal of Neuroscience.

[10]  W. Pardridge,et al.  Antisense gene therapy of brain cancer with an artificial virus gene delivery system. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  K. Avgoustakis,et al.  Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. , 2004, Current drug delivery.

[12]  Hugo J Bellen,et al.  When cell biology meets development: endocytic regulation of signaling pathways. , 2002, Genes & development.

[13]  E. Shusta,et al.  Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation , 2007, Pharmaceutical Research.

[14]  D. Bazile,et al.  Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. , 1995, Journal of pharmaceutical sciences.

[15]  Rongqin Huang,et al.  Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain. , 2007, Journal of biomedical science.

[16]  L. Lim,et al.  Mechanistic study of the uptake of wheat germ agglutinin-conjugated PLGA nanoparticles by A549 cells. , 2004, Journal of pharmaceutical sciences.

[17]  Yan Zhang,et al.  Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[18]  D. Walker,et al.  Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. , 1993, The American journal of pathology.

[19]  W. Pardridge,et al.  Blood-brain barrier delivery. , 2007, Drug discovery today.

[20]  K. Avgoustakis,et al.  Effect of preparative variables on the properties of poly(dl-lactide-co-glycolide)-methoxypoly(ethyleneglycol) copolymers related to their application in controlled drug delivery. , 1999, International journal of pharmaceutics.

[21]  I. Legen,et al.  Polarised transport of monocarboxylic acid type drugs across rat jejunum in vitro: the effect of mucolysis and ATP-depletion. , 2003, International journal of pharmaceutics.

[22]  W. Pan,et al.  Activation of urocortin transport into brain by leptin , 2000, Peptides.

[23]  T. Suhara,et al.  Pharmacokinetics and brain uptake of lactoferrin in rats. , 2006, Life sciences.

[24]  Y Li,et al.  PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[25]  L. Facci,et al.  Corticotropin-releasing factor (CRF) and related peptides confer neuroprotection via type 1 CRF receptors , 2003, Neuropharmacology.

[26]  Rachel C Brown,et al.  Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells , 2007, Brain Research.

[27]  U. Ungerstedt.  Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. , 1971, Acta physiologica Scandinavica. Supplementum.

[28]  M. Wirth,et al.  Lectin-mediated drug delivery: binding and uptake of BSA-WGA conjugates using the Caco-2 model. , 2002, International journal of pharmaceutics.

[29]  P. Couvreur,et al.  Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery , 2001, Pharmaceutical Research.

[30]  Bong-Hee Lee,et al.  Corticotropin-releasing Factor (CRF) and Urocortin Promote the Survival of Cultured Cerebellar GABAergic Neurons Through the Type 1 CRF Receptor , 2006, Journal of Korean medical science.

[31]  Drug targeting to the brain. , 2007, Annual review of pharmacology and toxicology.

[32]  W. Fogel,et al.  Assessment of plasma lactoferrin in Parkinson's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.

[33]  F. Calon,et al.  Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. , 2003, Human gene therapy.

[34]  Y Agid,et al.  Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[36]  Y. Suzuki,et al.  Mammalian lactoferrin receptors: structure and function. , 2005, Cellular and molecular life sciences : CMLS.

[37]  J. Huwyler,et al.  Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  H. Lee,et al.  Synthesis of Pegylated Immunonanoparticles , 2002, Pharmaceutical Research.

[39]  Amarnath Sharma,et al.  Liposomes in drug delivery: Progress and limitations , 1997 .

[40]  G. Storm,et al.  Targeting Anti—Transferrin Receptor Antibody (OX26) and OX26-Conjugated Liposomes to Brain Capillary Endothelial Cells Using In Situ Perfusion , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[41]  L. Fenart,et al.  Receptor-mediated Transcytosis of Lactoferrin through the Blood-Brain Barrier* , 1999, The Journal of Biological Chemistry.

[42]  Mehrdad Hamidi,et al.  Brain drug targeting: a computational approach for overcoming blood-brain barrier. , 2009, Drug discovery today.

[43]  J. Shapiro,et al.  Endocytosis and Signal Transduction: Basic Science Update , 2003, Biological research for nursing.

[44]  A. Lees,et al.  The corticotrophin‐releasing factor‐like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease , 2007, The European journal of neuroscience.